2024-11-16 12:25:17
Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia
Corporate/ 2023-07-24
Everest Medicines Announces Completion o...

SHANGHAI,May 17,2023-- Everest Medicines (HKEX 1952.HK,"Everest",or the "Company"),a biopharmaceutical company focused o...

DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Health/ 2023-07-22
DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATIO...

Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%.

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release